|  |  |  |
| --- | --- | --- |
| **Supplementary Table 1.** Baseline clinical and tumor pathological characteristics. Data are shown for all patients with metastatic breast cancer included in the TEX clinical trial and the subset of patients included in whole genome transcriptional analyses. | | |
| **Factor** | **All Patients** | **Transcriptional profiling** |
|  | **(N=304)** | **(N=85)** |
|  | **N (%)** | **N (%)** |
| **Age at diagnosis** |  |  |
| Median (Range) | 50 (27-71) | 51 (30-69) |
| < 50 years | 154 (51%) | 36 (43%) |
| ≥ 50 years | 149 (49%) | 48 (57%) |
| Missing/unknown | 1 | 1 |
|  |  |  |
| **Primary tumor ER status** |  |  |
| Positive | 215 (76%) | 50 (63%) |
| Negative | 68 (24%) | 29 (37%) |
| Missing/unknown | 21 | 6 |
|  |  |  |
| **Primary tumor PR status** |  |  |
| Positive | 151 (57%) | 34 (47%) |
| Negative | 114 (43%) | 39 (53%) |
| Missing/unknown | 39 | 12 |
|  |  |  |
| **Primary tumor histological grade** |  |  |
| Grade 1/2 | 121 (49%) | 22 (41%) |
| Grade 3 | 125 (51%) | 32 (59%) |
| Missing/unknown | 58 | 31 |
|  |  |  |
| **Primary tumor size** |  |  |
| ≤ 20 mm | 119 (40%) | 30 (37%) |
| > 20 mm | 180 (60%) | 51 (63%) |
| Missing/unknown | 5 | 4 |
|  |  |  |
| **Primary tumor nodal status** |  |  |
| N0 | 92 (31%) | 24 (30%) |
| N+ | 203 (69%) | 57 (70%) |
| Missing/unknown | 9 | 4 |
|  |  |  |
| **Adjuvant chemotherapy** |  |  |
| Yes | 150 (49%) | 38 (45%) |
| No | 152 (50%) | 46 (55%) |
| Missing/unknown | 2 | 1 |
|  |  |  |
| **Adjuvant endocrine therapy** |  |  |
| Yes | 156 (52%) | 39 (46%) |
| No | 147 (48%) | 45 (54%) |
| Missing/unknown | 1 | 1 |
|  |  |  |
| **Adjuvant radiotherapy** |  |  |
| Yes | 214 (71%) | 50 (60%) |
| No | 87 (29%) | 34 (40%) |
| Missing/unknown | 3 | 1 |
|  |  |  |
| **Metastatic category** |  |  |
| Loco-regional | 50 (17%) | 24 (28%) |
| Bone | 56 (18%) | 14 (16%) |
| Lung | 63 (21%) | 14 (16%) |
| Liver | 133 (44%) | 33 (39%) |
| Missing/unknown | 2 |  |
|  |  |  |
| **No of metastatic sites** |  |  |
| Oligo metastasis (n=1) | 76 (25%) | 17 (20%) |
| Multiple metastases (n>1) | 226 (75%) | 68 (80%) |
| Missing/unknown | 2 | 0 |
|  |  |  |
| **Metastasis-free interval** |  |  |
| ≤ 24 months | 80 (26%) | 30 (36%) |
| > 24 months | 223 (74%) | 54 (64%) |
| Missing/unknown | 1 | 1 |
|  |  |  |
| **Molecular subtype** |  |  |
| Luminal A | 65 (37%)a | 5 (6%)b |
| Luminal B | 81 (45%)a | 26 (31%)b |
| HER2-enriched | 9 (5%)a | 27 (32%) |
| Triple-negativea/Basal-likeb | 24 (14%)a | 24 (29%)b |
| Normal-likeb | n.a. | 2 (2%)b |
| Unclassified/missing | 125 | 1 |
| a= St Gallen subtype, b=PAM50 intrinsic subtype | |  |
| Metastatic categories were specified by this classification: loco-regional; locally advanced or regional metastases in the lymph nodes or skin, bone; skeletal metastases with or without loco-regional metastases, lung; plural metastases with or without skeletal and loco-regional metastases, and liver; hepatic metastases with or without plural, skeletal or loco-regional metastases. | | |